Product image of Munalea 20 (Desogestrel, Ethinylestradiol) supplied by GNH India

Munalea 20

Active Ingredient:
Desogestrel, Ethinylestradiol
Origin:
EU

Munalea 20 (Desogestrel, Ethinylestradiol)

Desogestrel/Ethinylestradiol, the active ingredient in Munalea 20, is a combined oral contraceptive presented as a tablet for oral use. It works by inhibiting ovulation, thickening cervical mucus, and altering the endometrial lining to prevent pregnancy in women of reproductive age.

GNH India supplies Munalea 20 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets, and ensuring product integrity from manufacturing to delivery through rigorous testing.

Manufacturer / TM Owner

Hormosan Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Munalea 20, a combined oral contraceptive, is indicated for hormonal contraception in women.
  • Contraception: prevention of pregnancy in women of reproductive age.
  • Acne management: reduction of inflammatory acne lesions when prescribed for dermatological benefit.
  • Dysmenorrhea treatment: relief of painful menstrual cramps associated with ovulatory cycles.

How It Works

  • Desogestrel binds to progesterone receptors and suppresses the mid‑cycle luteinizing hormone surge, preventing ovulation. Ethinylestradiol, a synthetic estrogen, stabilises the endometrial lining and enhances the progestin’s effect on cervical mucus, making it thicker and less permeable to sperm. Together they provide synergistic hormonal control of the hypothalamic‑pituitary‑ovarian axis to inhibit fertilisation and implantation.

Side Effects

Munalea 20 may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Nausea: mild to moderate stomach upset, often transient.
  • Headache: tension‑type or migraine‑like pain.
  • Breast tenderness: swelling or discomfort of the breasts.
  • Irregular bleeding: spotting or changes in menstrual flow.

Serious or Rare Side Effects

  • Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism.
  • Hypertensive disorders: new‑onset or worsening high blood pressure.
  • Liver dysfunction: cholestatic jaundice or hepatic adenoma.

Precautions & Warnings

Before prescribing Munalea 20, clinicians should evaluate individual risk factors and counsel patients on safe use.

  • Assess thrombotic risk: review personal and family history of clotting disorders.
  • Screen for hypertension: monitor blood pressure prior to initiation.
  • Avoid smoking: especially in women over 35 years of age.
  • Consider hepatic function: adjust use in liver disease.
  • Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Avoid Interactions

Munalea 20 can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

  • Antiepileptic enzyme inducers (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy.
  • Rifampin and other strong CYP3A4 inducers: can markedly decrease hormone levels.
  • Antiretroviral protease inhibitors (e.g., ritonavir): may increase hormone concentrations leading to adverse effects.

Moderate Interactions (Monitor Closely)

  • Antifungal azoles (e.g., ketoconazole): may increase hormone levels, monitor for side effects.
  • St. John’s wort: may modestly reduce effectiveness, advise backup contraception.
  • Selective serotonin reuptake inhibitors: may increase risk of bleeding, observe.

Frequently Asked Questions

Munalea 20 is a combined oral contraceptive indicated for the prevention of pregnancy in women of reproductive age. It is also prescribed in some regions for the management of acne and for relief of dysmenorrhoea associated with ovulatory cycles.

Desogestrel acts as a progestin, suppressing the luteinising hormone surge and thereby inhibiting ovulation. Ethinylestradiol provides estrogenic activity that stabilises the endometrium and thickens cervical mucus, creating an environment that is hostile to sperm and implantation.

The dosing regimen for Munalea 20 is determined by the prescribing clinician. Typically, the product is taken as one tablet daily at the same time each day, but the exact schedule and any missed‑dose instructions are provided by the healthcare professional.

Munalea 20 is not intended for use during pregnancy and should be discontinued if pregnancy occurs. While limited data exist for breastfeeding, the combined estrogen component may reduce milk production; clinicians usually advise caution and assess risks versus benefits.

To order Munalea 20, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Munalea 20 contains desogestrel and ethinylestradiol, offering a low‑dose progestin with a favourable bleeding profile. Compared with older formulations, it may have a slightly lower risk of androgenic side effects, but the overall efficacy in preventing pregnancy is comparable to other approved combined pills.

Store Munalea 20 at ambient temperature, preferably below 25 °C. Keep the tablets in the original blister pack, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Munalea 20 is taken orally as a tablet. Patients should swallow one tablet each day, preferably at the same time, with or without food. Consistent daily intake helps maintain steady hormone levels and maximises contraceptive effectiveness.

The most serious risks include venous thromboembolism, arterial thrombosis such as stroke or myocardial infarction, severe hypertension, and liver disorders. Patients should be educated to recognise symptoms like unexplained leg pain, chest discomfort, severe headache, or jaundice and seek immediate medical attention.

Munalea 20 is contraindicated in women with a history of thromboembolic disease, current pregnancy, known or suspected breast cancer, uncontrolled hypertension, severe liver disease, or those who smoke heavily (more than 15 cigarettes per day) and are over 35 years old.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Desogestrel, Ethinylestradiol

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT